Drug Profile
SCH 532706
Latest Information Update: 20 Jun 2016
Price :
$50
*
At a glance
- Originator Schering-Plough
- Class Antivirals; Small molecules
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for HIV-1 infections (Combination therapy) in Australia (PO)
- 06 Mar 2007 Phase-I clinical trials in HIV-1 infections (Combination therapy) in Australia (PO)